Area of research
Cardiology and Cardiovascular Medicine · Physiology
Research interest
Research interests include Acute Myocardial Infarction Research, Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, and Erythrocyte Function and Pathophysiology.
Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58
Convergence of SARS-CoV-2 spike antibody levels to a population immune setpoint
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
Tracking immune correlates of protection for emerging SARS-CoV-2 variants
Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021–August 2022
Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61
Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in <scp>DECLARE‐TIMI</scp> 58
Hypertrophic cardiomyopathy in myosin-binding protein C (<i>MYBPC3</i>) Icelandic founder mutation carriers
Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients
Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk
Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”
Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program